LadRx Corporation (0I5R.L)

1.0000 -1.4600 (-59.35%) As of 06:49PM BST. Market open.

LadRx Corporation

11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
310 826 5648
https://www.ladrxcorp.com

Sector(s): 
Industry: 
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Stephen Snowdy Ph.D.	Chief Executive Officer	545k	N/A	1970
Mr. John Y. Caloz	CFO, Treasurer Senior VP & Corporate Secretary	416k	N/A	1952
Molly Carey Poarch	Global & U.S. Head of Corporate Communications	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company's Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Corporate governance

LadRx Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.